ReviewInternational journal of molecular sciences2026
Cytokines and Chemokines as Emerging Biomarkers and Therapeutic Targets in Colorectal Cancer-Narrative Review.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- NKR-P1A/CD161: A Multifunctional Immune Receptor at the Crossroads of Antitumor Immunity.Biomolecules · 2026Review
- CD47 and FOXP3Cancers · 2026Review
- CCL2: A Pro-Inflammatory Driver and Candidate Diagnostic Biomarker in Colorectal Cancer Patients.International journal of molecular sciences · 2026Article
- The Aging Microenvironment Shapes Angiogenic Remodeling in IBD-Associated Colorectal Carcinogenesis.Aging cell · 2026Review
- Cytokine and chemokine networks in colorectal cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a significant global health challenge, characterized by an increasing incidence rate and high mortality rate. Early detection and effective treatment are crucial to improving patients' quality of life. Cytokines and chemokines are key modulators of the tumor microenvironment, influencing the recruitment of immune cells, angiogenesis, proliferation, and metastasis. This narrative review summarizes the current knowledge regarding the potential diagnostic and therapeutic applications of selected cytokines and chemokines in CRC. We discuss their potential as biomarkers for early detection, prognosis, and prediction of treatment response. We also highlight emerging therapeutic strategies targeting cytokine and chemokine pathways, including immune checkpoint inhibitors, modulation of chemokine signaling, and the direct use of cytokines to enhance antitumor immunity, with particular emphasis on interleukin-6 (IL-6), C-X-C motif chemokine ligand 8 (CXCL8), C-C motif chemokine ligand 2 (CCL2), and the C-X-C motif chemokine ligand 12 (CXCL12)-C-X-C chemokine receptor type 4 (CXCR4) axis, which show consistent associations with tumor stage, metastasis, and treatment response. Integrating cytokine- and chemokine-based approaches with combination therapies could lead to more effective conventional treatments. In summary, this review emphasizes the potential of cytokines and chemokines as diagnostic tools and therapeutic targets, paving the way for more personalized and effective treatment strategies for colorectal cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.